Andelyn Biosciences & Amplo Biotech Partner on AAV Gene Therapy Manufacturing

Andelyn Biosciences Inc., a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Amplo Biotechnology, a pioneer in adeno-associated virus (AAV) regenerative medicines for neuromuscular junction (NMJ) affecting conditions, to provide scalable manufacturing of clinical-grade AAV material leveraging Andelyn’s suspension AAV Curator platform.

Diseases of the NMJ typically result in muscle weakness with severe cases requiring the use of respiratory support, the use of wheelchair for ambulation, and/or tube feeding. In some cases, NMJ disorders can be life-threatening.

Andelyn Biosciences’ suspension AAV Curator platform is a highly characterized, scalable, suspension AAV platform that leverages a data-driven approach to adapt and optimize customer processes while providing a pathway to cGMP and commercial manufacturing. By adopting this platform, Amplo Biotechnology aims to advance its AAV gene therapy programs toward clinical evaluation, focusing on the safety and efficacy required for upcoming trials.

“As a leading clinical and commercial CDMO, we are honored to support Amplo Biotechnology’s efforts to bring hope to patients affected by debilitating NMJ diseases,” said Matt Niloff, Chief Commercial Officer at Andelyn Biosciences. “Our Curator platform and end-to-end capabilities are designed to help partners achieve key development and clinical milestones.”